ImpediMed (IPD) H1 2026 earnings summary

Executive summary

• Revenue for 1H FY26 reached A$7.5m, up 25%, driven mainly by higher SOZO Usage Fees and expansion into Heart Health and Weight Management markets.

• SOZO® unit sales grew to 102 globally, with significant expansion outside the US.

• Gross margin remained strong at 87%, slightly down from 88% in the prior period.

• Cash and cash equivalents stood at A$18.8m at period end, supporting 6.5 quarters of operations.

• Net loss widened to $12.3m from $11.1m year-over-year, reflecting higher operating expenses.

Financial highlights

• Total revenue: $7.5m (up from $6.0m year-over-year); gross profit: $6.6m (up from $5.3m year-over-year); gross margin steady at 87%.

• Adjusted EBITDA loss was A$8.1m; reported EBITDA loss was A$8.8m.

• Operating expenses: $18.1m (up from $17.3m year-over-year).

• Operating cash outflow totaled A$8.5m; customer receipts were A$7.2m.

• Borrowings increased to $20.9m from $13.8m at 30 June 2025.

Outlook and guidance

• 2H FY26 expected to see strengthening commercial momentum in oncology survivorship and new Heart Health and body composition markets.

• Focus on disciplined capital management and operational efficiency as commercial operations scale.

• The company expects to continue generating operating losses and net cash outflows from operations in the near term.

• Future viability depends on raising additional capital and maintaining access to borrowing facilities.

• Priorities include driving SOZO® sales, accelerating Heart Health market entry, launching body composition solutions, and leveraging expanded board expertise.